Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter ... MarketWatch RITUXAN(R) (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. "With a strong start for TECFIDERA in the U.S., as well as approvals in ... Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results - Earnings Call ... |
